Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

類似資料

• A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
  著者:: Zimmer, Alexandra S., 等
  出版事項: (2019)
• Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
  著者:: Lampert, Erika J., 等
  出版事項: (2020)
• Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women’s cancers
  著者:: Peer, Cody J., 等
  出版事項: (2017)
• Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
  著者:: Lee, Jung-Min, 等
  出版事項: (2017)
• Effects of the poly(ADP-ribose) polymerase inhibitor olaparib in cerulein-induced pancreatitis
  著者:: Ahmad, Akbar, 等
  出版事項: (2020)